Circassia Ltd, which is testing a novel immunotherapy for four major allergies, has announced plans to float on the main market of the London Stock Exchange. At an estimated £175 million, the initial public offering would be one of the UK’s largest. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
